ClinicalTrials.gg
CompletedNCT02260544Updated Sep 23, 2016

Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection

A Phase 1 interventional study of Doxorubicin Hydrochloride Liposome Injection in Ovarian Epithelial Cancer Recurrent, sponsored by Dr. Reddy's Laboratories Limited. Completed at 11 sites in India. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2016-09-23.

Sponsored by Dr. Reddy's Laboratories Limited · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing liposomal doxorubicin in Carcinoma, Ovarian Epithelial — none open to participants now, none under way, none of them phase 3. liposomal doxorubicin · Carcinoma, Ovarian Epithelial.

Enrollment
5th of 14
49 · median 33
Started
2014
the only one that year
Phase 1
4 of 14
none open now
Registered
10th of 14
by date
Lead sponsor
1 of 14
Dr. Reddy's Laboratories Limited

Among the 14 studies testing liposomal doxorubicin in Carcinoma, Ovarian Epithelial, this one is the 5th largest by enrollment, is the only one that started in 2014, is one of 4 in phase 1, and was the 10th registered.

Carcinoma, Ovarian Epithelial

798 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 102 are open to participants now.

Browse Carcinoma, Ovarian Epithelial studies →

Open to participants now

None of the 14 studies testing liposomal doxorubicin in Carcinoma, Ovarian Epithelial is open now. The open studies under Carcinoma, Ovarian Epithelial, anywhere →

About liposomal doxorubicin

liposomal doxorubicin: first FDA approval 1995 (DOXIL (LIPOSOMAL)), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 75 Carcinoma, Ovarian Epithelial studies recruiting now, 50 (67%) set no upper age limit and 12 (16%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 60 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing liposomal doxorubicin in Carcinoma, Ovarian Epithelial as a file.
02

Study summary

Bioequivalence study is proposed to be carried out on patients of ovarian cancer, who are already receiving or who in the opinion of their treating physicians are candidates for Doxorubicin liposomal injection therapy .

Read the detailed description

This study has sequential two stage design. Bioequivalence based on encapsulated doxorubicin will be tested at the end of stage 1. Power analysis will be performed for the primary pharmacokinetic parameters of free Doxorubicin and liposome encapsulated Doxorubicin, for all completed patients before bioequivalence evaluation. If observed power will be >= 80% then two one-sided 90% CI will be calculated for bioequivalence assessment at stage I.

If observed power will be \< 80% then bioequivalence will be evaluated at stage I. If bioequivalence met then study will be stopped and if bioequivalence not met, then required additional patients will be enrolled in stage II.

Each patient will be randomized to one of the two treatment sequences ( RT or TR ) according to a randomization scheme prepared prior to the start of the trial. Serial blood samples for determination of free doxorubicin and liposomal encapsulated doxorubicin plasma concentration for PK analysis will be obtained in each cycle .

Bioequivalence Criteria : The 94.12% confidence intervals for the ratio of geometric least squares means of ln-transformed pharmacokinetic parameters Cmax, AUC0-t and AUC0-inf should be within 80.00 to125.00% to conclude the test product is bioequivalent to the reference product.

03

Conditions studied

  • Ovarian Epithelial Cancer Recurrent
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female of Indian Nationality , between 18-60n years of age
  • Able to understand nature of this study and give written prior to the participation in the trial.
  • Patients with ovarian cancer requiring Doxorubicin and whose disease has progressed or recurred after platinum-based chemotherapy and who are already receiving or scheduled to start therapy with reference listed drug
  • performance status ≤ 2
  • Cardiac function ( ) ≥ 50%
  • patient with of at least 3 months
  • Adequate hematopoietic, renal and liver function

Exclusion criteria

Exclusion Criteria:

  • Prior doxorubicin exposure that would result in a total lifetime exposure of 550mg/m2 or more after four cycles of treatment .
  • Pregnant or breast-feeding female
  • active opportunistic infection with mycobacteria , cytomegalovirus , toxoplasma
  • Impaired cardiac function including any of the following conditions within past 6 months :

    1. Unstable angina
    2. prolongation or other significant abnormalities
    3. Coronary artery bypass graft surgery
  • History of reactions attributed to a conventional formulation of doxorubicin HCl or the components of Doxorubicin Hydrochloride liposome injection.
  • known
  • positive antibody or syphilis
  • Patients with significantly impaired hepatic function
  • liver and kidney disease
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Test Product - T

    doxorubicin hydrochloride liposome ( Dr. Reddy's Lab ) Use the test drug (doxorubicin hydrochloride liposome Injection 20mg/10mL i.e. 2mg/mL from Dr.Reddy's Laboratories Ltd., India) ; then use the reference drug ( doxorubicin hydrochloride liposome Injection 20mg/10mL i.e. 2mg/mL from Sun Pharma ) after at least 4-weeks.

    Drug: Doxorubicin Hydrochloride Liposome Injection

  • Active comparator
    Reference Product - R

    doxorubicin hydrochloride liposome ( Sun Pharma ) Use the reference drug (doxorubicin Hydrochloride Liposome Injection 20mg/10mL i.e. 2mg/mL; from Sun Pharma ) ; then use the test drug ( doxorubicin hydrochloride liposome Injection 20mg/10mL i.e. 2mg/mL from Dr.Reddy's Laboratories Ltd., India) after at least 4 weeks.

    Drug: Doxorubicin Hydrochloride Liposome Injection

Interventions

  • 50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation , After completion of Cycle 2 ( Day 28) , patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome injection upto 4 more cycles if tolerance permits under guidance of their attending physicians.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic ( PK ) parameter : the maximum plasma doxorubicin concentration ( Cmax ) [ Time frame : 2 cycles ]

    The study end point will use PK parameter ( Cmax ) for free doxorubicin and liposome encapsulated doxorubicin

    Time frame: 58 days

  2. PK parameter : the areas under the plasma concentration versus time curve calculated from 0 to the last measurable observation ( AUC 0-t)

    The study endpoint will use the PK parameter ( AUC 0-t) for free doxorubicin and liposome encapsulated doxorubicin ( AUC 0-t)

    Time frame: 58 days

  3. PK parameter : the areas under the plasma concentration versus time curve extrapolated from 0 to infinity ( AUC 0-inf)

    The study endpoint will use the PK parameter ( AUC 0-Inf) for free doxorubicin and liposome encapsulated doxorubicin

    Time frame: 58 days

Secondary outcomes

  1. Incidence of treatment-emergent adverse events ( TEAEs)

    Time frame: 58 days

07

Study locations

11 sites
  • City Cancer Center
    Vijaywada, Andhra Pradesh, India
  • Nirmal Hospital Pvt Ltd
    Surat, Gujarat, India
  • Srinivasam Cancer Care Hospitals India Private Limited
    Bangalore, Karnataka, India
  • Erode Cancer Center
    Erode, Karnataka, India
  • Cancer Clinic and Nursing Home & Jasleen Hospital
    Nagpur, Maharahtra, India
  • Curie Manavta Cancer Centre
    Nashik, Maharashtra, India
  • Acharya HariHar Regional Cancer Centre
    Cuttack, Orissa, India
  • Meenakshi Mission Hospital & Research Centre
    Madurai, Tamil Nadu, India
  • Dr. G. Viswanathan Speciality Hospitals
    Trichy, Tamil Nadu, India
  • Bibi General Hospital
    Hyderabad, Telangana 500034, India
  • MNJ Institute of Oncology & Regional Cancer Centre
    Hyderabad, Telangana, India
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Apr 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2014
First posted
Oct 9, 2014
Start
Jul 2014
Primary completionActual
Apr 2015
CompletionActual
Aug 2015
Last update
Sep 23, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02260544
Responsible party
Sponsor
First posted
Oct 9, 2014
Start date
Jul 2014
Primary completion
Apr 2015
Completion
Aug 2015
Last update
Sep 23, 2016

Study contacts

Ashis Patnaik, MBBS, MD
study director · Dr. Reddy's Laboratories Limited

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal doxorubicin

Start the discussion